Literature DB >> 17627278

Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation.

Carlos le Sage1, Remco Nagel, David A Egan, Mariette Schrier, Elly Mesman, Annunziato Mangiola, Corrado Anile, Giulio Maira, Neri Mercatelli, Silvia Anna Ciafrè, Maria Giulia Farace, Reuven Agami.   

Abstract

MicroRNAs (miRNAs) are potent post-transcriptional regulators of protein coding genes. Patterns of misexpression of miRNAs in cancer suggest key functions of miRNAs in tumorigenesis. However, current bioinformatics tools do not entirely support the identification and characterization of the mode of action of such miRNAs. Here, we used a novel functional genetic approach and identified miR-221 and miR-222 (miR-221&222) as potent regulators of p27(Kip1), a cell cycle inhibitor and tumor suppressor. Using miRNA inhibitors, we demonstrate that certain cancer cell lines require high activity of miR-221&222 to maintain low p27(Kip1) levels and continuous proliferation. Interestingly, high levels of miR-221&222 appear in glioblastomas and correlate with low levels of p27(Kip1) protein. Thus, deregulated expression of miR-221&222 promotes cancerous growth by inhibiting the expression of p27(Kip1).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627278      PMCID: PMC1949005          DOI: 10.1038/sj.emboj.7601790

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  36 in total

1.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Authors:  M Loda; B Cukor; S W Tam; P Lavin; M Fiorentino; G F Draetta; J M Jessup; M Pagano
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

2.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.

Authors:  P L Porter; K E Malone; P J Heagerty; G M Alexander; L A Gatti; E J Firpo; J R Daling; J M Roberts
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma.

Authors:  H Mineta; K Miura; I Suzuki; S Takebayashi; H Amano; K Araki; H Harada; K Ichimura; J P Wennerberg; M R Dictor
Journal:  Cancer       Date:  1999-03-01       Impact factor: 6.860

4.  Translational control of p27Kip1 accumulation during the cell cycle.

Authors:  L Hengst; S I Reed
Journal:  Science       Date:  1996-03-29       Impact factor: 47.728

5.  Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma.

Authors:  C D Lu; S Morita; T Ishibashi; H Hara; H Isozaki; N Tanigawa
Journal:  Cancer       Date:  1999-03-15       Impact factor: 6.860

6.  Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest.

Authors:  S S Millard; J S Yan; H Nguyen; M Pagano; H Kiyokawa; A Koff
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

7.  The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.

Authors:  Xiao-Feng Le; Francois-Xavier Claret; Amy Lammayot; Ling Tian; Deepa Deshpande; Ruth LaPushin; Ana M Tari; Robert C Bast
Journal:  J Biol Chem       Date:  2003-04-16       Impact factor: 5.157

Review 8.  Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation.

Authors:  A Alessandrini; D S Chiaur; M Pagano
Journal:  Leukemia       Date:  1997-03       Impact factor: 11.528

9.  Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation.

Authors:  Christine Mayr; Michael T Hemann; David P Bartel
Journal:  Science       Date:  2007-02-22       Impact factor: 47.728

10.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression.

Authors:  M L Fero; E Randel; K E Gurley; J M Roberts; C J Kemp
Journal:  Nature       Date:  1998-11-12       Impact factor: 49.962

View more
  353 in total

1.  MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma.

Authors:  Kai Sun; Wei Wang; Jun-jie Zeng; Cheng-tang Wu; Shang-tong Lei; Guo-xin Li
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 3.  Emerging role of microRNAs in drug-resistant breast cancer.

Authors:  Sarmila Majumder; Samson T Jacob
Journal:  Gene Expr       Date:  2011

4.  Environmental chemical exposures and human epigenetics.

Authors:  Lifang Hou; Xiao Zhang; Dong Wang; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2011-12-13       Impact factor: 7.196

Review 5.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

6.  Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling.

Authors:  María J Bueno; Marta Gómez de Cedrón; Usua Laresgoiti; José Fernández-Piqueras; Ana M Zubiaga; Marcos Malumbres
Journal:  Mol Cell Biol       Date:  2010-04-19       Impact factor: 4.272

7.  Pumilio turns on microRNA function.

Authors:  Robinson Triboulet; Richard I Gregory
Journal:  Nat Cell Biol       Date:  2010-10       Impact factor: 28.824

Review 8.  The microRNA networks of TGFβ signaling in cancer.

Authors:  V P Sivadas; S Kannan
Journal:  Tumour Biol       Date:  2013-12-10

9.  miR-146b-5p regulates cell growth, invasion, and metabolism by targeting PDHB in colorectal cancer.

Authors:  Yuanzeng Zhu; Gang Wu; Wenfeng Yan; Han Zhan; Peichun Sun
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

10.  SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers.

Authors:  Nathan J Schuld; Andrew D Hauser; Adam J Gastonguay; Jessica M Wilson; Ellen L Lorimer; Carol L Williams
Journal:  Cell Cycle       Date:  2014-01-16       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.